Drug Delivery Technology: Revolutionizing CNS Therapies


Full Paper

Interactive Report

Price: £150.00
Description: This INTERACTIVE report provides a detailed analysis of key player and technologies under development to improve the delivery of new and approved CNS therapies, particularly with respect to crossing the blood brain barrier.

More information on Interactive Reports (opens in new tab)

Full Paper

Full Paper

Price: £150.00
Description: This report provides a detailed analysis of key player and technologies under development to improve the delivery of new and approved CNS therapies, particularly with respect to crossing the blood brain barrier.

Full Paper

Executive Summary

Price: £15.00
Description: This is a precisé of the key findings of companies and technologies under development to overcome delivery issues associated with crossing the blood brain barrier and improve the delivery of new and approved CNS therapies.

Full Paper

PowerPoint Presentation

Price: £50.00
Description: A powerpoint presentation of 20 tables and 23 figures included in the full report; with relevant annotations.

Research Report Overview

Published Date: 13/12/2007
Category: Drug Delivery & Devices

Research Report Decription

pdf icon

Sample Pages:

Click here (PDF)

This report gives in depth analysis of innovative drug delivery technologies that are being applied to the delivery agents to treat central nervous system conditions and diseases such as Alzhemier's disease, Parkinson's diseases and glioblastomas. The report analyzes innovative delivery technologies which overcome the blood brain barrier (BBB) to enable the targeted delivery of small molecules, macromolecules and cells in situ or in vivo and via a variety of delivery routes.

Key Questions Answered:

  • How will the drug delivery technology drivers change in the CNS arena during the next decade and  beyond?
  • What are the key delivery technologies and devices in the CNS field?
  • When are products and medical devices which utilize these key delivery technologies likely to reach the market?
  • Which drug delivery technologies are likely to win in the near-term and the long-term, and why?
  • Which companies are the winners in each technology category?
  • How are drug delivery technologies evolving to meet the demands of the CNS market?
  • Where are the market opportunities now and in the future?

Companies Mentioned:

Aastrom, Ablynx, Abbott Laboratories, Acadia Pharmaceuticals, Actelion, Alkermes, Alseres Pharmaceuticals, Altea Therapeutics, ALZA Corporation, Anesiva, Amarin, Arena, AstraZeneca, ArmaGen Technologies, Astellas, Axonyx, Biogen Idec, Boehringer Ingelheim Bristol-Myers-Squibb, Boston Life Sciences, Brookwood Pharmaceuticals, Cenomed BioSciences, CeNeRx, Ceregene,Clinical Data Online, Inc., Corcept, Cortex Pharmaceuticals, Copernicus Therapeutics, Cyberkinetics, Dainippon Sumitomo, Dermatrends, D-Pharm, DOV Pharmaceuticals, Durect, Elan Corporation, Eli Lilly, EKOS, Endo Pharmaceuticals, Epix, Esai, Fabre-Kramer, Forest Laboratories, GlaxoSmithKline, GPI Pharma, Generex, Genzyme Corporation, Glide Pharma, GW Pharmaceutical, Janssen, Juvantia Pharma, Johnson & Johnson, Inflazyme Pharmaceuticals, Ipsen, Ivax, Intranasal Therapeutics, King Pharmaceuticals, Kurve Technologies, Kyowa Lundbeck, Medtronics, MediciNova, Memory Pharmaceuticals, Midatech, MAP Pharmaceuticals, Medical Technologies, Merck & Co., Merck Serono, Migenix, Myriad Genetics, Nabi Pharmaceuticals, Nanopharm, NeuroWave, Neuro3d, Neurocrine, Neurogen, Neurologix, NiTi Medical Technologies, NeoPharm, NeuroSearch, Neurocrine, Northwest Biotherapeutics, Novartis, NPS, Ono Pharmaceuticals, Otsuka Pharmaceutical, Organon, Ovation Pharmaceuticals, Oxford BioMedica, Pain Therapeutics, Pharmidex UK, Pharmos, Perfusion Technology, Pfizer, Phase 2 Discovery, Potomac Pharma, Predix Pharmaceuticals, Prescient, Repligen, Roche, Saegis Pharmaceuticals, Sanofi-aventis, Schering-Plough, Schering AG, Schwarz Pharma, Sepracor, Servier, Shire Pharmaceuticals, New River Pharmaceuticals, SK Pharmaceuticals, Solvay Pharmaceuticals, Sosei, Spherics, SurModics, Tanabe, Takeda, Teikoku Pharmaceuticals, Tissue Repair Cell Technology, Transpharma Medical, Targacept, Tetragenex, Teva Pharmaceuticals, Tikvah Pharmaceuticals, Titan Pharmaceuticals, Torrey Pines Therapeutics, Toyama Chemical, Trans-Tech Pharma, UCB, Valeant Pharmaceuticals, Vanda Pharmaceuticals, Wyeth, Xytis, Zogenix

Paper Highlights:

  • 2006 global CNS market worth over US$100 billion.
  • The CNS market has attracted attention of specialty pharma and big pharma players such as Abbot, Astellas, AstraZeneca, Biogen, Boehringer Ingelheim Bristol-Myers Squibb, Dianippon Sumitomo, Eisai, Eli-Lilly, Forest Laboratories, GlaxoSmithKline, Lundbeck , Johnson & Johnson, Merck & Co., Novartis, Otsuka, Pfizer, Sanofi-aventis, Schering AG, Merck Serono, Shire, Takeda, Tanabe, UCB and Wyeth.
  • Challenges remain to ensure the efficient and targeted delivery of agents across the blood brain barrier by invasive and non-invasive delivery methods to a provide flexible, reproducible and cost-effective method of managing CNS disorders.
  • Specialists are applying a plethora of platforms to deliver CNS agents and regenerative therapies, including needle free delivery, transdermal, intranasal, pulmonary, oral & buccal delivery systems.
  • Many new classes of drugs will reach the market over the next 6 years, driving future market growth including small molecules, peptides and regenerative therapies (stem cells and gene therapies). Their success is analyzed in detail and case studies provided to highlight the progress of each technology.
  • The application of nanotechnologies including micellar nanoparticles, nanoparticles, nanocells and lipobridge systems offers significant opportunities for selective and targeted delivery of CNS products. A number of nano-enabled delivery systems are evaluated in this report.
  • As the CNS market evolves new approaches totreatment of CNS are emerging utilizing stem cells and gene-based therapies. Several companies are working towards this goal including: Copernicus Therapeutics, Genzyme, Oxford Biomedica, NeuroGeneration and Pharmidex. A number of delivery options are currently being evaluated to optimize the clinical utility of these regenerative therapies and are analyzed in detail in the report.